PMID- 35047390
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240405
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 11
DP  - 2021
TI  - Survival Outcomes of Patients With Mediastinal Germ Cell Tumors: Experience of a 
      Cancer Center in South America.
PG  - 758496
LID - 10.3389/fonc.2021.758496 [doi]
LID - 758496
AB  - PURPOSE: Mediastinal germ cell tumors (GCT) are rare neoplasms associated with 
      poor survival prognosis. Due to their low incidence, limited information is 
      available about this disease in South America. The objective of this study is to 
      report the clinical characteristics and outcomes of patients with mediastinal GCT 
      in a cancer center in Colombia. MATERIALS AND METHODS: We conducted a 
      retrospective analysis of patients with mediastinal GCT treated at the National 
      Cancer Institute at Bogota (Colombia) between 2008 and 2020. Survival curves were 
      presented using the Kaplan-Meier method. Chi-square and Cox proportional hazard 
      model tests were used for data analysis. RESULTS: Sixty-one patients were 
      included in the study. Of them, 60 were male and 51 (83.6%) of whom had 
      non-seminomatous germ cell tumors (NSGCT). Twenty-nine patients (47.5%) presented 
      with superior vena cava syndrome, and 18 (29.5%) patients had extrapulmonary 
      metastatic involvement. The three-year overall survival (OS) of NSGCT patients 
      was 26%. The 3-year OS of NSGCT patients who underwent surgical resection of 
      residual mediastinal mass after chemotherapy was 59%. Non-surgical management 
      after first-line chemotherapy was associated with a worse survival prognosis in 
      NSGCT patients (p = 0.002). Ten patients with mediastinal seminomatous germ cell 
      tumors (SCGT) achieved a 3-year OS of 100%. CONCLUSION: Mediastinal NSGCT had 
      poor outcomes. Surgery of the residual mass after first-line chemotherapy seems 
      to improve the outcome of NSGCT patients. Advanced disease at presentation may 
      reflect inadequate access to reference cancer centers in Colombia and potentially 
      explain poor survival outcomes in this cohort. On the other hand, mediastinal 
      SCGT is a biologically different disease; most patients will achieve disease 
      remission and long-term survival with first-line chemotherapy.
CI  - Copyright (c) 2022 Vallejo-Yepes, Carvajal-Fierro, Bruges-Maya, Beltran, Buitrago, 
      Beltran-Jimenez and Carreno-Duenas.
FAU - Vallejo-Yepes, Camilo
AU  - Vallejo-Yepes C
AD  - Clinical Oncology, National Cancer Institute, Universidad El Bosque, Bogota, 
      Colombia.
FAU - Carvajal-Fierro, Carlos Andres
AU  - Carvajal-Fierro CA
AD  - Thoracic Surgery, National Cancer Institute, Bogota, Colombia.
FAU - Bruges-Maya, Ricardo
AU  - Bruges-Maya R
AD  - Clinical Oncology, National Cancer Institute, Universidad El Bosque, Bogota, 
      Colombia.
FAU - Beltran, Julian
AU  - Beltran J
AD  - Interventional Radiology, National Cancer Institute, Bogota, Colombia.
FAU - Buitrago, Ricardo
AU  - Buitrago R
AD  - Thoracic Surgery, National Cancer Institute, Bogota, Colombia.
FAU - Beltran-Jimenez, Rafael
AU  - Beltran-Jimenez R
AD  - Thoracic Surgery, National Cancer Institute, Bogota, Colombia.
FAU - Carreno-Duenas, Jose Alexander
AU  - Carreno-Duenas JA
AD  - Research Department, National Cancer Institute, Bogota, Colombia.
LA  - eng
PT  - Journal Article
DEP - 20220103
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC8761649
OTO - NOTNLM
OT  - Colombia
OT  - South America
OT  - mediastinal neoplasms
OT  - non-seminomatous germ cell tumor
OT  - seminoma
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/01/21 06:00
MHDA- 2022/01/21 06:01
PMCR- 2021/01/01
CRDT- 2022/01/20 06:05
PHST- 2021/08/14 00:00 [received]
PHST- 2021/12/07 00:00 [accepted]
PHST- 2022/01/20 06:05 [entrez]
PHST- 2022/01/21 06:00 [pubmed]
PHST- 2022/01/21 06:01 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2021.758496 [doi]
PST - epublish
SO  - Front Oncol. 2022 Jan 3;11:758496. doi: 10.3389/fonc.2021.758496. eCollection 
      2021.